Pitt Street Research Briefing on Prescient Therapeutics (ASX: PTX)
Reach Markets interviewed Co-Founder and Senior Analyst of Pitt Street Research, Stuart Roberts, who released a research report on PTX which discusses Prescient’s flagship asset – PTX-100 – and how they are addressing a disease with a significantly unmet need.
During this session, Stuart discusses:
- The report which highlights the encouraging preliminary Phase 1b data and the considerable market opportunity for a new and effective drug in TCL, which is a disease that is underserved by existing therapies.
- Their valuation of PTX as outlined in last November’s initiation report, at 11.6c per share base case and 16.3c per share in an optimistic (or bull) case.
- While only around 5,000-6,000 people a year will be diagnosed with a T-Cell Lymphoma in the US alone, the market opportunity could be in the billions, citing Acrotech Biopharma’s Folotyn with its $842,585 per patient per year price tag as a guide.
Recorded on 14th March 2024 (AEDT)
Featured Speaker
Stuart Roberts
Co-Founder and Senior Analyst at Pitt Street Research
Stuart covered healthcare and biotechnology for the stockbroking firms Southern Cross Equities, Bell Potter and Baillieu Holst from 2002 to 2015 where he developed a reputation for detailed analysis on previously uncovered Life Science companies. After 15 months working for two ASX-listed drug development companies in 2015 and early 2016 he returned to equities research, co-founding Pitt Street Research.
